Read by QxMD icon Read

Rcc ihc

Lu Yu, Jun Li, Sanpeng Xu, Mariajose Navia Miranda, Guoping Wang, Yaqi Duan
BACKGROUND: Xp11.2 translocation/transcription factor E3 (TFE3) rearrangement renal cell carcinoma (RCC) is a rare subtype of RCC with limited clinical and pathological data. CASE PRESENTATION: Here we present an unusual high-grade Xp11.2 translocation RCC with a rhabdoid feature and SMARCB1 (INI1) inactivation in a 40-year-old man with end-stage kidney disease. The histological examination of the dissected left renal tumor showed an organoid architecture of the eosinophilic or clear neoplastic cells with necrosis and high mitotic activity...
October 12, 2016: Diagnostic Pathology
Hongjuan Zhao, Rosalie Nolley, Andy M W Chan, Erinn B Rankin, Donna M Peehl
MET plays an important role in the development and progression of papillary renal cell carcinoma (pRCC). Evaluation of efficacy of MET inhibitors against pRCC has been hampered by limited preclinical models depicting MET abnormalities. We established a new patient-derived xenograft (PDX) model of pRCC carrying an activating mutation of MET and tested the ability of cabozantinib, an inhibitor of receptor tyrosine kinases including MET, to inhibit tumor growth and metastasis. Precision-cut, thin tissue slices from a pRCC specimen obtained by nephrectomy were implanted under the renal capsule of RAG2(-/-)γC(-/-) mice to establish first generation TSG-RCC-030...
August 11, 2016: Cancer Biology & Therapy
Franziska Erlmeier, Arndt Hartmann, Michael Autenrieth, Max Wiedemann, Philipp Ivanyi, Sandra Steffens, Wilko Weichert
Immune checkpoint inhibitors targeting the inhibitory cross talk between tumor and immune cells have been approved for therapy in renal cell carcinoma (RCC). In contrast to clear cell RCC, little is known on PD-1/PD-L1 expression patterns in rarer RCC subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of PD-1 and PD-L1 expression in chromophobe (ch)RCC. Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimen was analyzed for PD-1 and PD-L1 expression by immunohistochemistry...
November 2016: Medical Oncology
John Cogswell, H David Inzunza, Qiuyan Wu, John N Feder, Gabe Mintier, James Novotny, Diana M Cardona
AIM: Nivolumab, a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has activity in melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin lymphoma. Nivolumab is approved in the USA and EU for advanced melanoma, NSCLC, and RCC, and relapsed Hodgkin lymphoma in the USA. Programmed death-ligand 1 (PD-L1), a PD-1 ligand, is expressed on mononuclear leukocytes, myeloid cells, and tumor cells. PD-L1 is being investigated as a potential biomarker to predict the association of tumor PD-L1 expression with nivolumab efficacy...
September 26, 2016: Molecular Diagnosis & Therapy
Arezoo Rasti, Maryam Abolhasani, Leili Saeednejad Zanjani, Mojgan Asgari, Mitra Mehrazma, Zahra Madjd
PURPOSE: Cancer stem cells (CSCs) represent a population with tumour-initiating, self-renewal, and differentiation potential. This study aimed to evaluate the expression patterns and clinical significance of chemokine receptor type 4 (CXCR4) as a novel CSC marker in renal cell carcinoma (RCC). METHODS: The expression of CXCR4 was examined in 173 well-defined renal tumour tissues, including 106 (61.5 %) clear cell renal cell carcinomas (ccRCCs), 35 (20 %) papillary renal cell carcinomas (pRCCs), and 32 (18...
September 16, 2016: Journal of Cancer Research and Clinical Oncology
Steven C Smith, Kiril Trpkov, Ying-Bei Chen, Rohit Mehra, Deepika Sirohi, Chisato Ohe, Andi K Cani, Daniel H Hovelson, Kei Omata, Jonathan B McHugh, Wolfram Jochum, Maurizio Colecchia, Mitual Amin, Mukul K Divatia, Ondřej Hes, Santosh Menon, Isabela Werneck da Cunha, Sergio Tripodi, Fadi Brimo, Anthony J Gill, Adeboye O Osunkoya, Cristina Magi-Galluzzi, Mathilde Sibony, Sean R Williamson, Gabriella Nesi, Maria M Picken, Fiona Maclean, Abbas Agaimy, Liang Cheng, Jonathan I Epstein, Victor E Reuter, Satish K Tickoo, Scott A Tomlins, Mahul B Amin
An emerging group of high-grade renal cell carcinomas (RCCs), particularly carcinomas arising in the hereditary leiomyomatosis renal cell carcinoma syndrome (HLRCC), show fumarate hydratase (FH) gene mutation and loss of function. On the basis of similar cytomorphology and clinicopathologic features between these tumors and cases described as tubulocystic carcinomas with poorly differentiated foci (TC-PD) of infiltrative adenocarcinoma, we hypothesized a relationship between these entities. First, 29 RCCs with morphology of TC-PD were identified retrospectively and assessed for FH expression and aberrant succination (2SC) by immunohistochemistry (IHC), with targeted next-generation sequencing of 409 genes-including FH-performed on a subset...
September 15, 2016: American Journal of Surgical Pathology
Laurence Albiges, A Ari Hakimi, Wanling Xie, Rana R McKay, Ronit Simantov, Xun Lin, Jae-Lyun Lee, Brian I Rini, Sandy Srinivas, Georg A Bjarnason, Scott Ernst, Lori A Wood, Ulka N Vaishamayan, Sun-Young Rha, Neeraj Agarwal, Takeshi Yuasa, Sumanta K Pal, Aristotelis Bamias, Emily C Zabor, Anders J Skanderup, Helena Furberg, Andre P Fay, Guillermo de Velasco, Mark A Preston, Kathryn M Wilson, Eunyoung Cho, David F McDermott, Sabina Signoretti, Daniel Y C Heng, Toni K Choueiri
PURPOSE: Obesity is an established risk factor for clear cell renal cell carcinoma (RCC); however, some reports suggest that RCC developing in obese patients may be more indolent. We investigated the clinical and biologic effect of body mass index (BMI) on treatment outcomes in patients with metastatic RCC. METHODS: The impact of BMI (high BMI: ≥ 25 kg/m(2) v low BMI: < 25 kg/m(2)) on overall survival (OS) and treatment outcome with targeted therapy was investigated in 1,975 patients from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and in an external validation cohort of 4,657 patients...
September 6, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Pedram Argani, Victor E Reuter, Lei Zhang, Yun-Shao Sung, Yi Ning, Jonathan I Epstein, George J Netto, Cristina R Antonescu
Renal cell carcinomas (RCCs) with the t(6;11)(p21;q12) chromosome translocation are low-grade RCC which often occur in young patients. They typically feature an unusual biphasic morphology characterized by nests of larger epithelioid cells surrounding intraluminal collections of smaller cells clustered around basement membrane material. The t(6;11)(p21;q12) translocation fuses the Alpha (MALAT1) gene with the TFEB transcription factor gene, resulting in upregulated expression of intact native TFEB that drives the aberrant expression of melanocytic markers which is a hallmark of this distinctive neoplasm...
November 2016: American Journal of Surgical Pathology
Marie Jeanneau, Valerie Gregoire, Claude Desplechain, Fabienne Escande, Dan Petre Tica, Sebastien Aubert, Xavier Leroy
We report an exceptional case of renal cell carcinoma (RCC) associated with ALK translocation in an adult. The tumor was located in the left kidney and measured 4cm. The tumor was composed of sheets of large eosinophilic cells with frequently intracytoplasmic vacuoles. The nuclei were large with a nucleolar grade 3. At immunohistochemistry, tumor cells were diffusely positive for PAX8 and vimentin and focally stained with CK7. ALK immunostaining was diffuse and fluorescent in situ hybridization showed a rearrangement of ALK in numerous tumor cells...
August 2, 2016: Pathology, Research and Practice
Xing Huang, Lei Wang, Yuan Chen, Xinmin Zheng, Xinghuan Wang
PURPOSE: The study aimed to investigate the expression of thymidine phosphorylase (TP) in renal cell carcinoma (RCC) and its correlation with clinicopathological features and thrombocytosis, and also to determine their prognostic significance. PATIENTS AND METHODS: TP expression in 127 RCC specimens was evaluated with immunohistochemistry assays. Platelet (PLT) counts of patients before surgery were recorded. Correlations among TP expression, PLT and the clinicopathological features of the patients and their prognostic values were studied statistically...
August 18, 2016: Urologia Internationalis
Gyula Kovacs, Nina Kaerger Billfeldt, Nelli Farkas, Timea Dergez, Andras Javorhazy, Daniel Banyai, Csaba Pusztai, Arpad Szanto
AIMS: The aim of this study was to investigate the potential of ß-catenin as biomarker for predicting cancer specific survival and find a reproducible mode of evaluation of immunohistochemistry. METHODS AND RESULTS: Expression of the ß-catenin was analysed by immunohistochemistry in a cohort of 488 patients with conventional RCC operated between 2000 and 2010. Association between ß-catenin expression and cancer specific survival was assessed by univariate and multivariate Cox regression model in relation conventional clinical pathological prognostic factors and by Kaplan-Meier survival analysis with Log rank test...
August 8, 2016: Histopathology
Shuji Mikami, Mototsugu Oya, Ryuichi Mizuno, Takeo Kosaka, Masaru Ishida, Naoto Kuroda, Yoji Nagashima, Ken-Ichi Katsube, Yasunori Okada
The purpose of this article is to review the recent advances in renal cell carcinoma (RCC) from a pathological point of view. Because the genetic features and morphological characteristics have become major criteria for the classification of RCC, special techniques, such as immunohistochemistry, are essential to the differential diagnosis of renal tumors. Metastasis is frequently observed among the RCC patients with curative nephrectomy, and extracellular matrix-degrading enzymes, such as matrix metalloproteinases (MMP) and heparanase, play a key role in invasion and metastasis of RCC...
September 2016: Pathology International
Ji-Gen Ping, Fei Wang, Jin-Xian Pu, Ping-Fu Hou, Yan-Su Chen, Jin Bai, Jun-Nian Zheng
Cullin1 (Cul1) is a scaffold protein of the ubiquitin E3 ligase Skp1/Cullin1/Rbx1/F-box protein complex, which ubiquitinates a broad range of proteins involved in cell-cycle progression, signal transduction, and transcription. To investigate the role of Cul1 in the development of renal cell carcinoma (RCC), we evaluated the Cul1 expression by immunohistochemistry using a tissue microarray (TMA) containing 307 cases of RCC tissues and 34 normal renal tissues. The Cul1 expression was increased significantly in RCC and was correlated with renal carcinoma histology grade (P = 0...
July 23, 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
Tyler M Bauman, Wei Huang, Moon Hee Lee, E Jason Abel
Endothelial markers PECAM-1 (CD31) and endoglin (CD105) may be used to identify endothelium and activated endothelium respectively, with the CD105:CD31 ratio used to measure neovascularity. This study investigated the hypothesis that neovascularity in renal cell carcinoma (RCC) is associated with more aggressive RCC tumors and can be used to predict oncological outcomes. Multiplexed immunohistochemistry using antibodies to detect endoglin and PECAM-1 was performed on a tissue benign kidney samples and RCC tumors including clear cell, papillary, chromophobe and collecting duct and unclassified tumors (combined for statistics), and multispectral imaging was used for analysis...
July 16, 2016: Human Pathology
Vivian Thimsen, Annett Hölsken, Michael Buchfelder, Jörg Flitsch, Rudolf Fahlbusch, Harald Stefanits, Marco Losa, David T W Jones, Rolf Buslei
The epithelial cell adhesion molecule (EpCAM) is a type I glycoprotein located on the surface of epithelial cells. It is strongly expressed in many neoplasms and already used in the diagnosis and distinction of various tumour subtypes. Comparative studies about EpCAM expression in cystic sellar lesions are lacking. Therefore, we analysed its distribution pattern in adamantinomatous (aCP) and papillary (pCP) craniopharyngiomas (CP) and Rathke's Cleft Cysts (RCC) using immunohistochemistry and gene expression profiling...
2016: Scientific Reports
Andras Javorhazy, Nelli Farkas, Tamas Beothe, Csaba Pusztai, Arpad Szanto, Gyula Kovacs
PURPOSE: In spite of early detection of conventional renal cell carcinoma (RCC) by widespread use of abdominal imaging, approximately 10-15 % of patients will die due to disease. The aim of this study was to identify new biomarkers predicting the postoperative progression of conventional RCC. METHODS: Tissue multiarrays (TMA) of conventional RCC from a cohort of 486 patients were analysed by immunohistochemistry for expression of the transmembrane protein TMEM27, which was identified as a candidate biomarker by Affymetrix U133 Plus 2...
September 2016: Journal of Cancer Research and Clinical Oncology
Megan L Troxell, John P Higgins
Kidney transplant recipients are at increased risk of malignancy, with about 5% incidence of cancer in native end-stage kidneys. Carcinoma in the renal allograft is far less common. Prior studies have demonstrated a propensity for renal cell carcinomas of papillary subtypes in end stage kidneys, and perhaps in allograft kidneys, but most allograft studies lack detailed pathologic review and predate the current classification system. We reviewed our experience with renal carcinoma in kidney allografts at 2 academic centers applying the ISUP classification, informed by immunohistochemistry...
July 7, 2016: Human Pathology
I Tsimafeyeu, A Khasanova, E Stepanova, M Gordiev, D Khochenkov, A Naumova, I Varlamov, A Snegovoy, L Demidov
BACKGROUND: Up to date, there are no data about FGFR2 expression and its predictive role in papillary RCC (pRCC) patients. The aim of the present study was to test FGFR2 expression and mutations for association with survival outcome in patients with pRCC. METHODS: Specimens of removed primary tumors from 214 untreated metastatic pRCC patients were evaluated by immunohistochemistry with FGFR2 antibody. FGFR2 mutations were assessed by PCR and direct sequencing, with DNA obtained from 62 paraffin-embedded pRCC samples...
July 5, 2016: Clinical & Translational Oncology
Deng-Shuang Wu, Cheng Chen, Zhen-Jie Wu, Bing Liu, Li Gao, Qing Yang, Wei Chen, Jun-Ming Chen, Yi Bao, Le Qu, Lin-Hui Wang
BACKGROUND: Activating transcription factor 2 (ATF2) is a basic helix-loop-helix transcription factor, which has been shown to participate in the pathobiology of numerous cancers. However, the role of ATF2 in renal cell carcinoma (RCC) remains unclear. METHODS: ATF2 knockdown and overexpression studies were performed in RCC cells to evaluate changes in cell viability, cell cycle, apoptosis, migration and invasion. Xenograft models were used to examine the tumorigenic and metastatic capability of RCC cells upon ATF2 suppression...
2016: Journal of Experimental & Clinical Cancer Research: CR
Q I Chen, Bin Cao, Ning Nan, Y U Wang, X U Zhai, Youfang Li, Tie Chong
The function of kinesin family member 18A (KIF18A) in human renal cell carcinoma (RCC) is unclear. The purpose of the current study was to determine the expression and prognostic significance of KIF18A in RCC. Specimens from 273 RCC patients undergoing nephrectomies were studied. Expression of KIF18A mRNA was examined by reverse transcription-polymerase chain reaction (RT-PCR) or quantitative PCR, and the expression of KIF18A protein was examined by immunohistochemistry and western blotting. The expression of KIF18A in clear-cell RCC cell lines was decreased using small interfering RNA targeting KIF18A, and increased by transfection with KIF18A cDNA...
July 2016: Experimental and Therapeutic Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"